Subject category:
Strategy and General Management
Published by:
IBS Case Development Center
Length: 15 pages
Data source: Published sources
Topics:
Dr Reddy's Laboratories Limited; Ranbaxy Laboratories Limited; Drug discovery; Research and development (R&D); Indian pharmaceutical industry; Novartis; Active pharmaceutical ingredients; Pfizer, Inc; Generic drugs; Bulk active pharmaceuticals; Branded generics; Specialty pharmaceutical; United States Food and Drug Administration; New drug application; Abbreviated new drug application
Share a link:
https://casecent.re/p/19702
Write a review
|
No reviews for this item
This product has not been used yet
Abstract
With India''s shift from current process patent regime to product patent regime, post 2005, a host of top Indian drug firms such as Dr Reddy''s, Ranbaxy, Wockhardt, Lupin Laboratories and others, realised early that they need to do their own drug-discovery research. Dr Reddy''s is one of the leading players in the Indian pharmaceutical industry. The company is also one of the leading active pharmaceutical ingredient (API) and generics players in the top pharma markets of the world. It has also challenged and won a lawsuit against the world''s leading pharmaceutical company, Pfizer, for norvasc (the world''s top-selling hypertension medicine) with its generic version. The company, after being successful in its bulk active (API) and generic business is heading towards new drug discovery. By 2008, the company intends to be among the top 50 global pharmaceutical companies and by 2013 among the top 25. Will the company be successful in its new avatar of being a discovery-led global pharmaceutical company? The case offers rich insights into Dr Reddy''s strategy of heading towards new drug discovery and being a discovery-led global pharmaceutical company.
About
Abstract
With India''s shift from current process patent regime to product patent regime, post 2005, a host of top Indian drug firms such as Dr Reddy''s, Ranbaxy, Wockhardt, Lupin Laboratories and others, realised early that they need to do their own drug-discovery research. Dr Reddy''s is one of the leading players in the Indian pharmaceutical industry. The company is also one of the leading active pharmaceutical ingredient (API) and generics players in the top pharma markets of the world. It has also challenged and won a lawsuit against the world''s leading pharmaceutical company, Pfizer, for norvasc (the world''s top-selling hypertension medicine) with its generic version. The company, after being successful in its bulk active (API) and generic business is heading towards new drug discovery. By 2008, the company intends to be among the top 50 global pharmaceutical companies and by 2013 among the top 25. Will the company be successful in its new avatar of being a discovery-led global pharmaceutical company? The case offers rich insights into Dr Reddy''s strategy of heading towards new drug discovery and being a discovery-led global pharmaceutical company.